| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | 0.084 | 0.05 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.072 | 0.05 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.05 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.05 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.05 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.05 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.077 | 0.05 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.07 | 0.06 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.06 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.06 |